GSK (GSK) to Release Earnings on Wednesday

GSK (NYSE:GSK) is expected to announce its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect GSK to post earnings of $0.66 per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 6:00 AM ET.

GSK (NYSE:GSK) last released its earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.22. GSK had a return on equity of 48.64% and a net margin of 17.16%.The business had revenue of $11.35 billion for the quarter, compared to analysts’ expectations of $8.21 billion. During the same quarter in the prior year, the firm earned $0.50 earnings per share. The firm’s revenue was up 6.7% on a year-over-year basis. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

GSK Stock Up 1.1%

Shares of NYSE GSK opened at $50.89 on Wednesday. The company has a current ratio of 0.84, a quick ratio of 0.55 and a debt-to-equity ratio of 0.95. The firm has a market capitalization of $103.74 billion, a PE ratio of 14.38, a price-to-earnings-growth ratio of 1.48 and a beta of 0.45. The firm has a fifty day simple moving average of $48.76 and a two-hundred day simple moving average of $44.04. GSK has a 12 month low of $32.38 and a 12 month high of $51.46.

Insider Activity

In related news, major shareholder Plc Gsk bought 1,470,000 shares of GSK stock in a transaction on Thursday, December 11th. The stock was acquired at an average price of $19.00 per share, with a total value of $27,930,000.00. Following the acquisition, the insider directly owned 18,245,691 shares of the company’s stock, valued at $346,668,129. This represents a 8.76% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 10.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in GSK. BI Asset Management Fondsmaeglerselskab A S lifted its stake in GSK by 28.2% during the 2nd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 121,249 shares of the pharmaceutical company’s stock valued at $4,656,000 after acquiring an additional 26,685 shares during the period. AQR Capital Management LLC raised its stake in GSK by 84.4% in the first quarter. AQR Capital Management LLC now owns 40,239 shares of the pharmaceutical company’s stock worth $1,559,000 after buying an additional 18,420 shares in the last quarter. Brighton Jones LLC acquired a new stake in GSK in the 4th quarter worth approximately $528,000. Captrust Financial Advisors lifted its position in GSK by 11.0% during the second quarter. Captrust Financial Advisors now owns 85,080 shares of the pharmaceutical company’s stock valued at $3,267,000 after purchasing an additional 8,432 shares during the period. Finally, SkyView Investment Advisors LLC acquired a new position in shares of GSK in the second quarter worth about $303,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on GSK. Citigroup initiated coverage on GSK in a report on Tuesday. They issued a “neutral” rating for the company. Cfra set a $53.00 price target on GSK in a report on Thursday, October 30th. Jefferies Financial Group reiterated a “buy” rating on shares of GSK in a report on Monday, October 27th. Bank of America upgraded GSK from an “underperform” rating to a “neutral” rating in a research note on Tuesday, November 25th. Finally, Barclays lowered GSK from an “equal weight” rating to an “underweight” rating in a research report on Tuesday, January 6th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $44.13.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.